Advertisement

Myocardial Catecholamines and Inotropic Response in Heart Muscle Disease

  • P. M. Seferovič
  • R. Maksimovič
  • A. Ristič
  • S. Stepanovič
  • M. Ostojič
  • V. Kanjuh
  • D. Seferovič
  • S. Simeunovič
  • J. D. Vasilevič
Conference paper

Abstract

It is widely accepted that both humoral and tissue alterations of sympathetic nervous system activity exist in various heart muscle diseases, including in idiopathic dilated (IDC) and hypertrophic cardiomyopathy (HCM). In particular, there is increasing evidence that myocardial catecholamines may be important determinants of natural history, pathophysiology and prognosis of these patients.

Keywords

Hypertrophic Cardiomyopathy Idiopathic Dilate Cardiomyopathy Inotropic Response Plasma Norepinephrine Concentration Left Ventricular Ejection Frac 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Schofer J, Spielmann R, Schuchert A, Weber K, Schluter M (1988) Iodine-123 meta-iodobenzylguanidine scintigraphy: a noninvasive method to demonstrate myocardial adrenergic nervous system disintegrity in patients with idiopathic dilated cardiomyopathy. J Am Coll Cardiol 12:1252–1258PubMedCrossRefGoogle Scholar
  2. 2.
    Regitz V, Fleck E (1992) Myocardial adenine nucleotide concentrations and myocardial norepinephrine content in patients with heart failure secondary to idiopathic dilated or ischemic cardiomyopathy. Am J Cardiol 69:1574–1580PubMedCrossRefGoogle Scholar
  3. 3.
    Regitz V, Leuchs B, Bossaller C, Sehested J, Rappolder M, Fleck E (1991) Myocardial catecholamine concentrations in dilated cardiomyopathy and heart failure of different origins. Eur Heart J 12 [Suppl. D]:171–174PubMedCrossRefGoogle Scholar
  4. 4.
    De Maria R, Accinni R, Baroldi G, Repossini A, Garino-Cannia G, Caroli A, Vago T, Bevilacqua M, Pellegrini A (1990) Catecholamines, beta receptors and morphology in dilated cardiomyopathy: a preliminary report. In: Baroldi G, Camerini F, Goodwin JF (eds) Advances in cardiomyopathies. Springer, Berlin Heidelberg New York, pp 257–265CrossRefGoogle Scholar
  5. 5.
    Brush JE Jr, Eisenhofer G, Garty M, Stull R, Maron BJ, Cannon R (1989) Cardiac norepinephrine kinetics in hypertrophic cardiomyopathy. Circulation 79:836–844PubMedCrossRefGoogle Scholar
  6. 6.
    Seferovič PM, Stepanovič S, Maksimovič R, et al. (1997) Long-term prognosis in hypertrophie and idiopathic dilated cardiomyopathy: the role of myocardial catecholamine. Eur Heart J 18 [Suppl. A]:P3725Google Scholar
  7. 7.
    Correa-Araujo R, Oliveira JS, Ricciardi-Cruz A (1991) Cardiac levels of norepinephrine, dopamine, serotonin and histamine in Chagas’ disease. Int J Cardiol 31:329–36PubMedCrossRefGoogle Scholar
  8. 8.
    Da Prada M, Zürcher G (1976) Simultaneous radioenzymatic determination of plasma and tissue adrenaline, noradrenaline and dopamine within the femtomole range. Life Sci 19:1161–1174PubMedCrossRefGoogle Scholar
  9. 9.
    Weise VK, Kopin IJ (1976) Assay of catecholamines in human plasma. Studies of a single isotope radioenzymatic technique. Life Sci 19:1673–1686Google Scholar
  10. 10.
    Pauler JD, Johnson GA (1977) Simultaneous single isotope radioenzymatic assay of plasma norepinephrine, epinephrine and dopamine. Life Sci 21:625–636CrossRefGoogle Scholar
  11. 11.
    Seferovič PM, Stepanovič S, Maksimovič R et al. (1995) Myocardial catecholamine in primary heart muscle diseases: Fact or fancy? Eur Heart J 16 [Suppl. O]:124–127PubMedCrossRefGoogle Scholar
  12. 12.
    Seferovič PM, Stepanovič S, Maksimovič R, et al. (1997) Does myocardial catecholamine concentration reflect left ventricular function in heart muscle disease? J Am Coll Cardiol:796Google Scholar
  13. 13.
    Gilbert EM, Olsen SL, Renlund DG, Bristow MR (1993) Beta-adrenergic receptor regulation and left ventricular function in idiopathic dilated cardiomyopathy. Am J Cardiol 71:23–29CrossRefGoogle Scholar
  14. 14.
    Himura Y, Feiten SY, Kashiki M, Lewandowski TJ, Delehanty JM, Liang CS (1993) Cardiac noradrenergic nerve terminal abnormalities in dogs with experimental congestive heart failure. Circulation 88:1299–1309PubMedCrossRefGoogle Scholar
  15. 15.
    Perloff JK (1981) Pathogenesis of hypertrophie cardiomyopathy: hypothesis and speculations. Am Heart J 101:219–220PubMedCrossRefGoogle Scholar
  16. 16.
    Dargie H, Boschetti E, Reid J, Goodwin JF (1980) Autonomie function in hypertrophie cardiomyopathy. Circulation 2 [Suppl. III]:III–301Google Scholar
  17. 17.
    Sugishita Y, Iida K, Matsuda M, et al. (1983) Plasma norepinephrine concentration during exercise in patients with different types of hypertrophie cardiomyopathy. Annual Report of the Idiopathic Cardiomyopathy Research Committee, The Ministry of Health and Welfare of Japan Publication, Tokyo, pp 168–171Google Scholar
  18. 18.
    Maisel AS, Wright M, Wilner KD, Ziegler MG (1988) Norepinephrine kinetics in hypertrophie cardiomyopathy. In: Toshima H, Maron BJ (eds) Hypertrophic Cardiomyopathy. University of Tokyo Press, Tokyo, pp 129–139Google Scholar
  19. 19.
    Haneda T, Miura Y, Miyazawa K, et al. (1978) Plasma norepinephrine concentration in the coronary sinus in cardiomyopathies. Cath Cardiovasc Diag 4:399–405CrossRefGoogle Scholar
  20. 20.
    Toshima H, Koga Y (1988) Norepinephrine kinetics in hypertrophie cardiomyopathy. In: Toshima H, Maron BJ (eds) Hypertrophic Cardiomyopathy. University of Tokyo Press, Tokyo, pp 141–153Google Scholar
  21. 21.
    Pearse AGE (1964) The histochemistry and electron microscopy of obstructive cardiomyopathy. In: Wolstenhome GEW, O’Connor M (eds) Cardiomyopathies. G&A Churchill, London, pp 132–164CrossRefGoogle Scholar
  22. 22.
    McCallister BD, Brown AL (1967) A fine-structure study of idiopathic hypertrophie subaortic stenosis. Am J Cardiol 19:142–154CrossRefGoogle Scholar
  23. 23.
    Van Noorden S, Olsen EGJ, Pearse AGE (1971) Hypertrophic obstructive cardiomyopathy, a histological, histochemical and ultrastructural study of biopsy material. Cardiovasc Res 5:118–131PubMedCrossRefGoogle Scholar
  24. 24.
    Kawai C, Yui Y, Hoshono T, Sasayama S, Matsumori A (1983) Myocardial catecholamine in hypertrophic and dilated (congestive) cardiomyopathy: a biopsy study. J Am Coll Cardiol 2:834–840PubMedCrossRefGoogle Scholar
  25. 25.
    Beau SL, Saffitz JE (1994) Transmural heterogeneity of norepinephrine uptake in failing human hearts. J Am Coll Cardiol 23:579–585PubMedCrossRefGoogle Scholar
  26. 26.
    Schofer J, Tews A, Langes K, Bleifeld W, Reimitz PE, Mathey DG (1987) Relationship between myocardial norepinephrine content and left ventricular function — an endomyocardial biopsy study. Eur Heart J 8:748–753PubMedCrossRefGoogle Scholar
  27. 27.
    Anderson FL, Port D, Reid BB, Larrabee P, Hanson G, Bristow MR (1992) Myocardial catecholamine and neuropeptide Y depletion in failing ventricles of patients with idiopathic dilated cardiomyopathy. Correlation with beta adrenergic receptor downregulation. Circulation 85:46–53Google Scholar
  28. 28.
    Schofer J, Bleifeld W (1987) Sympathetic activity in idiopathic dilated cardiomyopathy. Influence of captopril and hydralazine. Cardiovasc Drugs Ther 1:177–181CrossRefGoogle Scholar
  29. 29.
    Regitz V, Bossaller C, Strasser R, Schuler S, Hetzer R, Fleck E (1990) Myocardial catecholamine content after heart transplantation. Circulation 82:620–623PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Italia 1998

Authors and Affiliations

  • P. M. Seferovič
  • R. Maksimovič
  • A. Ristič
  • S. Stepanovič
  • M. Ostojič
  • V. Kanjuh
  • D. Seferovič
  • S. Simeunovič
  • J. D. Vasilevič

There are no affiliations available

Personalised recommendations